SARS-CoV2 coronavirus: so far polite with children. Debatable immunological and non-immunological evidence

Main Article Content

F. Álvez

Keywords

SARS-CoV2, COVID-19, Innate, Adaptive, ACE2, Melatonin

Abstract

The reasons for the relative resistance of children to certain infections such as that caused by coronavirus SARS-CoV2 are not yet fully clear. Deciphering these differences can provide important information about the pathogenesis of the disease. Regarding the SARS-CoV2 virus, children are at the same risk of infection as the general population of all ages, with the most serious cases being found in infants. However, it has been reported that the disease is much less frequent than in adults and that most cases are benign or moderate (even with high viral loads), provided there are no other risk factors or underlying diseases. It is not clear why they have lower morbidity and virtually no mortality. A series of findings, relationships and behavioral patterns between the infectious agent and the child host may account for the lower incidence and a greatly attenuated clinical presentation of the disease in children.

Abstract 91 | PDF Downloads 96

References

1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Shilo T, et al. Epidemiology of COVID-19 among children in china. Pediatrics. 2020;145(6):e20200702.

2. Castagnoli R, Votto M, Licari A, Brambilla LL, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020, http://dx.doi.org/10.1001/jamapediatrics.2020.1467. Published online April 22.

3. Su L, Ma X, Yu H, Zhang Z, Bian P, Hang Y, et al. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. Emerg Microbes Infect. 2020;9:707-13.

4. Coronavirus Disease 2019 in Children-United States, February 12-Apryl 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422-6, http://dx.doi.org/10.15585/mmwr.mm6914e4external icon.

5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;00:1-8.

6. Pathak EB, Salemi JL, Sobers N, Menard J, Hambleton IR. COVID19 in Children in the United States: Intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract. 2020;(Apr), http://dx.doi.org/10.1097/PHH.0000000000001190 [Epub ahead of print].

7. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://drive.google.com/file/d/1ipwi9eASQGlliiQipfoaqMaSyyKPHshD/view?usp=sharing.

8. Kikkert MJ. Innate immune evasion by human respiratory RNA Viruses. J Innate Immun. 2020;12:4-20.

9. Lambert L, Culley FJ. Innate Immunity to Respiratory Infection in Early Life. Front Immunol. 2017;8:1570, http://dx.doi.org/10.3389/fimmu.2017.01570.

10. Shi Y, Wang Y, Shao Ch, Juang J, Gang J, Huang X, et al. COVID19 infection: the perspectives on immune responses. Cell Death
Differ. 2020;382:1-4.

11. Lee P-I, Hu Y-L, Chen P-Y, Huang Y-C, Hsueh P-R. Are children less susceptible to COVID19? J Microb Immunol Infect. 2020;(Feb), http://dx.doi.org/10.1016/j.jmii.2020.02.011).

12. Li G, Fan Y, Fan I, Lai Y, Han T, Li Z, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-32.

13. Zhao J, Zhao J, Perlman ST. Cell Responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-Infected mice. J Virol. 2010;84:9318-25.

14. Chen J, Lau YF, Lamirande EW, Paddock ChD, Bartlett JH, Zaki SR, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84:1289-301.

15. Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK - seventh update, 23 April 2020. Stockholm: ECDC; 2020.

16. Vaduganathan M, Vardeny O, Michel T, Mcmurray J, Pfeffer M, Solomon SD, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. New Engl J Med. 2020;(March), http://dx.doi.org/10.1056/NEJMsr2005760.

17. Xu H, Zhong L, Deng J, Pen J, Dan H, Zen X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:8, http://dx.doi.org/10.1038/s41368-020-0074-x.

18. Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594, http://dx.doi.org/10.1038/ncomms4594.

19. Jia H. Pulmonary angiotensin-converting enzyme 2 (ace2) and inflammatory lung disease. Shock. 2016;46:239-48.

20. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586-90.

21. Chen Y, Shan K, Qian W. Asians and other races express similar levels of and share the same genetic polymorphisms of the SARS-CoV-2 cell-entry receptor. Preprints. 2020, http://dx.doi.org/10.20944/preprints202002.0258.v1, 2020020258.

22. Song R, Preston G, Yosypiv IV. Ontogeny of angiotensin-converting enzyme 2. Pediatr Res. 2012;71:13-922.

23. Heimdal I, Moe N, Kokstad S, Christensen A, Skanke LA, NordbØ SA, et al. Human coronavirus in hospitalized children with respiratory tract infections: a 9-year population-based study from Norway. J Infect Dis. 2019;219:1198-206.

24. Monto AS, DeJonge P, Callear AP, Bazzi LA, Capriola S, Malosh RE, et al. Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J Infect Dis. 2020;(Apr), http://dx.doi.org/10.1093/infdis/jiaa161 [e-pub].

25. Chan CM, Tse H, Wong SS, Woo PC, Lau SK, Chen L, et al. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J Clin Virol. 2009;45:54-60.

26. Che XY, Qiu LW, Liao ZY, Wen K, Pan XY, et al. Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis. 2005;191:2033-7.

27. Green RJ, Annamalay A, Le Souëf P. Viral-bacterial interactions in childhood respiratory tract infections. Viral Infections in Children, volume 1. Switzerland: Springer International Publishing; 2017. p. 193-214.

28. Wölfel R, Corman VM, Guggemos WS, Seilmaier W, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID 2019. Nature. 2020, http://dx.doi.org/10.1038/s41586-020-2196-x. Advance online publication.

29. Shinjoh M, Omoe K, Saito N, Matsuo N, Nerome K. In vitro growth profiles of respiratory syncytial virus in the presence of influenza virus. Acta Virol. 2000;44:91-7.

30. Pinky L, Dobrovolny HM. Coinfections of the respiratory tract: viral competition for resources. PLoS One. 2016;11:e0155589, http://dx.doi.org/10.1371/journal.pone.0155589.

31. Pohanka M. Impact of melatonin on immunity: a review. Cent Eur J Med. 2013;8:369-76.

32. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583, http://dx.doi.org/10.1016/j.lfs.2020.117583.

33. Zhang Y, Li X, Jamison J, Wang N, Wang M, Yao J, et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res. 2016;60:405-14.

34. Shneider A, Kudriavtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol. 2020, http://dx.doi.org/10.1080/08830185.2020.1756284.

35. Shafinoori S, Ginocchio CC, Greenberg AJ, Yeoman E, Cheddie M, Rubin LJ, et al. Impact of pneumococcal conjugate vaccine and the severity of influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J. 2005;249:10-6.

36. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811-3.

37. Fathima P, Blyth CC, Lehmann D, Lim FJ, Abdalla T, de Klerk N, et al. The impact of pneumococcal vaccination on bacterial and viral Pneumonia in western australian children: Record Linkage Cohort Study of 469589 Births, 1996-2012. Clin Infect Dis. 2018;66:1075-85.

38. Blay A, Bessler H, Lahad A, Waitman DA, Djaldetti M. Does pneumococcal vaccine reduce influenza morbidity in humans?
Vaccine. 2007;25:1071-5.

39. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020, http://dx.doi.org/10.1038/s41591-020-0869-5.

40. Zimmermann P, Curtis N. Coronavirus infections in children including covid-19.: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis. 2020;39:355-68.